Our study found that direct medical costs were higher in oligoarticular JIA patients who were ANA positive or had an extended course and that medications account for over 80% of direct medical costs in patients with oligoarticular JIA. The gene discussed is BTG3; the disease is oligoarticular juvenile idiopathic arthritis.